Biotech and Pharma
Healthcare Stocks Are Just Starting Their Resurgence. Hold On to Them.
The healthcare sector is up 6% since early August, but is still cheap. And it’s got more room to run.
3 minute read
More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.
A bounty of new drugs are arriving through clinical trials.
4 minute read
Cytokinetics Stock Jumps. The Biotech’s Heart Drug Wows.
Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.”
2 minute read
Novo’s Wegovy Beats Lilly’s Zepbound for Heart Health, Study Finds. What It Means for Stocks.
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
2 minute read
How Novo Nordisk Hurt Denmark's Economy
The economy ministry blamed the slowdown on U.S. tariffs, but faltering demand for Ozempic and Wegovy could be another factor.
1 minute read
Healthcare Stocks Are ‘Priced at Panic Levels.’ It’s Time to Buy.
They’re bargains right now, according to two key measures. Expert Jim Paulsen won’t venture a guess when the prices will recover.
2 minute read
3 Reasons Not to Panic About Nvidia Earnings
Nvidia’s slim margin of outperformance wasn’t enough to satisfy the market. But there are grounds for optimism.
3 minute read
FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use
HHS Secretary Robert F. Kennedy Jr. says the shot will be available for people aged 5 and older.
2 minute read
Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients. The Stock Is Rising.
Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.’
3 minute read
The S&P 500 Keeps Rising. Stick With These Stocks.
Tech, consumer and industrial companies, and utilities have powered the index higher. They could keep gaining for a while.
2 minute read
Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.
The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.
4 minute read
Healthcare Stocks Are the Cheapest They‘ve Been in 30 Years—and a Turnaround May Have Already Started
For investors worried about elevated market valuations, they may be just what the doctor ordered.
3 minute read
Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.
The Covid-19 pandemic is over, but the virus persists
Long Read
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
The past year has been a disappointing one for gene therapies.
4 minute read
Nvidia Stock Drops 3.5%. Here’s Why Shares Were Down So Much Today.
Nvidia has agreed to pay 15% of the revenue generated from AI chip sales in China to the U.S. government.
2 minute read
The Biggest Stocks Are Still Winning. Why There’s Hope for the Whole S&P 500.
Analysts’ price forecasts are a hint that gains for stocks may broaden out beyond the usual suspects in big tech.
4 minute read
This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.
Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.
4 minute read
SPACs, Meme Stocks, and Hot IPOs Are Back. Why That’s a Warning for Markets.
Trump’s possible next move, Winklevoss twins jump into hot IPO market, Palo Alto Networks issues rosy guidance, and more news to start your day.
Long Read
A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock?
Shares have plunged by a third in the past year. Investors are worried about expiring patents for Keytruda, the cancer blockbuster.
4 minute read
Dayforce, Novo Nordisk, GoodRx, UnitedHealth, Sunrun, Duolingo, TeraWulf, and More Stock Market Movers
Dayforce soars following a report that says it could be bought by private-equity firm Thoma Bravo.
4 minute read
Novo Nordisk Stock Is Jumping. It Got Some Good Wegovy News.
Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.
2 minute read
Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.
GoodRx announces a collaboration with Novo Nordisk to make Ozempic cheaper for self-paying patients.
2 minute read
Vertex Pharma CEO Reshma Kewalramani Buys the Stock Dip
Biotech Vertex Pharmaceuticals stock tumbled on news of disappointing drug data. CEO Reshma Kewalramani paid nearly $4 million to buy shares.
1 minute read
Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes
The pricing of weight-loss drugs like Lilly’s Zepbound and Novo’s Wegovy is a pressure point for investors.
3 minute read
Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.
Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.
Long Read
